John David Finley - Aug 16, 2022 Form 4 Insider Report for PALISADE BIO, INC. (PALI)

Role
Chief Financial Officer
Signature
/s/ JD Finley
Stock symbol
PALI
Transactions as of
Aug 16, 2022
Transactions value $
$25,000
Form type
4
Date filed
8/18/2022, 09:04 PM
Previous filing
May 2, 2022
Next filing
Aug 25, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PALI Common Stock, par value $0.01 Purchase $25K +100K +456.7% $0.25 122K Aug 16, 2022 Direct F1
holding PALI Common Stock, par value $0.01 38.9K Aug 16, 2022 By FCW Investments, LLC F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PALI Series 1 Common Stock Purchase Warrant Purchase $0 +100K $0.00 100K Aug 16, 2022 Common Stock 100K $0.25 Direct F3
transaction PALI Series 2 Common Stock Purchase Warrant Purchase $0 +100K $0.00 100K Aug 16, 2022 Common Stock 100K $0.25 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents common shares underlying 100,000 Units of Issuer purchased by Reporting Person ("Units") in Underwritten Offering with each Unit containing (i) one share of common stock, (ii) one Series 1 Warrant and (iii) One Series 2 Warrant at a price per Unit of $0.25.
F2 Reporting Person is the managing member of FCW Investments LLC and has the sole investment and voting power over the securities held by this entity.
F3 Represents Series 1 Common Stock Purchase Warrants received as part of the Units purchased by Reporting Person. The Series 1 Warrants are exercisable upon receipt of stockholder approval per Nasdaq rules, which has not been obtained as of the date of this Form 4.
F4 Represents Series 2 Common Stock Purchase Warrants received as part of the Units purchased by Reporting Person. The Series 2 Warrants are exercisable upon receipt of stockholder approval per Nasdaq rules, which has not been obtained as of the date of this Form 4.